Cargando…
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
INTRODUCTION: Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast cancer cell lines. Combination of everolimus also known as RAD001 (oral mammalian target of rapamycin (mTOR) inhibitor) and carboplatin may have activity in metastatic triple-neg...
Autores principales: | Singh, Jasmeet Chadha, Novik, Yelena, Stein, Stacey, Volm, Matthew, Meyers, Marlene, Smith, Julia, Omene, Coral, Speyer, James, Schneider, Robert, Jhaveri, Komal, Formenti, Silvia, Kyriakou, Victoria, Joseph, Benson, Goldberg, Judith D, Li, Xiaochun, Adams, Sylvia, Tiersten, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053575/ https://www.ncbi.nlm.nih.gov/pubmed/24684785 http://dx.doi.org/10.1186/bcr3634 |
Ejemplares similares
-
Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
por: Bernard, Sarah, et al.
Publicado: (2021) -
Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells
por: Omene, Coral O., et al.
Publicado: (2011) -
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023) -
Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020) -
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)